Browse the evidence

Consuming ≥2 servings/week of sugar-sweetened beverages (SSBs) or artificially sweetened beverages (ASBs) is associated with a significantly higher risk of type 2 diabetes, even among adults who meet physical activity guidelines.

If you drink sugary or artificially sweetened beverages frequently (≥2 servings/week), your risk of type 2 diabetes increases, even if you exercise regularly. While exercise helps mitigate this risk, it does not cancel it out. To lower your diabetes risk, you should reduce your intake of these beverages in addition to staying active.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) achieve weight loss magnitudes (15-20%) comparable to bariatric surgery, significantly outperforming older pharmacotherapies and single-agonist GLP-1s.

If you have obesity, newer dual-agonist medications (like tirzepatide) are currently the most effective non-surgical treatment available, offering weight loss results similar to bariatric surgery. They work by targeting multiple hormonal pathways to reduce appetite and improve metabolism. Consult a doctor to see if you qualify based on your BMI and comorbidities.

Early response to treatment (≥5% weight loss in 3 months) is a strong predictor of long-term success; non-responders should switch therapies.

Monitor your weight closely in the first 3 months of starting a new obesity medication. If you haven't lost at least 5% of your body weight, talk to your doctor about switching to a different therapy. Early success is the best predictor of long-term success.

Endoscopic Sleeve Gastroplasty (ESG) using full-thickness suturing produces durable weight loss (mean 64-67% Excess Weight Loss at 12 months) and significant improvement/remission of metabolic comorbidities (T2DM, hypertension, NAFLD) in patients with BMI 30-50 kg/m2, outperforming lifestyle modifications and intragastric balloons.

ESG is a minimally invasive endoscopic procedure that reduces stomach volume and delays emptying to promote satiety. It is suitable for adults with BMI 30-50 who want a durable alternative to lifestyle changes or balloons, with high success rates for weight loss and metabolic improvement. It requires general anesthesia and has a low risk of serious complications.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, produces significant, dose-dependent reductions in body weight, BMI, and metabolic markers in obese adults with or without type 2 diabetes.

Retatrutide is a weekly injection that significantly reduces body weight (average ~14%) and improves metabolic health in obese adults, including those with type 2 diabetes. It works by targeting three hormone receptors (GLP-1, GIP, glucagon) to reduce appetite and improve insulin sensitivity. Higher doses (8-12 mg) generally produce greater weight loss. Common side effects include nausea and vomiting, which are often manageable. It is a prescription medication requiring medical supervision.

Combining bimagrumab (30 mg/kg IV every 12 weeks) with semaglutide (2.4 mg SC weekly) produces synergistic weight loss and body recomposition, achieving significantly greater fat mass reduction and lean mass preservation than either drug alone.

If you have obesity, combining a muscle-preserving antibody (bimagrumab) with a standard GLP-1 drug (semaglutide) yields significantly more fat loss and better muscle retention than using semaglutide alone. This suggests that targeting muscle preservation directly can enhance the efficacy of standard weight loss therapies.

In real-world clinical practice, tirzepatide produces significantly greater weight loss and higher rates of achieving 5%, 10%, and 15% weight reduction thresholds compared to semaglutide in adults with overweight or obesity.

If you are choosing between semaglutide and tirzepatide for weight loss, real-world data suggests tirzepatide is likely to produce roughly double the weight loss at one year compared to semaglutide. You are also significantly more likely to hit major weight loss milestones (5%, 10%, 15%) with tirzepatide. However, this comes with the caveat that these specific findings are based on formulations labeled for Type 2 Diabetes, and insurance coverage may be more difficult to obtain for tirzepatide than semaglutide.

A healthy low-carbohydrate diet (HLCD) combined with caloric restriction produces greater fat mass loss than caloric restriction alone in adults with overweight or obesity.

To lose fat effectively, try a healthy low-carb diet that cuts calories by about 25%. Focus on getting 30% of your calories from carbs (like whole grains and veggies), 50% from healthy fats (like nuts, oils, and avocados), and 20% from plant proteins. This approach helps you lose more fat than just eating less without changing what you eat.

Sustained, non-surgical, non-pharmacological weight loss from overweight (BMI ≥25) to healthy weight (BMI <25) during midlife (ages 40-50) is associated with a significantly decreased risk of incident chronic diseases (excluding type 2 diabetes) and all-cause mortality compared to persistent overweight.

If you are in midlife (40s-50s) and currently overweight, achieving and maintaining a healthy BMI (under 25) through lifestyle changes (diet and exercise) significantly lowers your risk of developing chronic diseases and dying prematurely compared to staying overweight. This benefit is independent of diabetes risk and does not require surgery or medication. The key is sustainability; the health benefits accrue over decades.

Adhering to the MyPlate dietary pattern (focusing on fruits, vegetables, whole grains, and protein) reduces central adiposity (waist circumference) in overweight, low-income patients, offering a practical alternative to calorie counting.

Follow the MyPlate guidelines: fill half your plate with fruits and vegetables, one-quarter with whole grains, and one-quarter with quality protein. You do not need to count calories. This approach helps reduce belly fat (waist circumference) and is easier to stick to long-term than strict calorie counting, especially if you find tracking numbers stressful.

Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, produces significant, dose-dependent weight loss in adults with obesity or overweight (≥1 comorbidity) over 13 weeks, with the 15 mg dose achieving a mean 14.7% reduction.

Take VK2735 once weekly as prescribed. Start with the lowest dose (2.5 mg) and follow the titration schedule to minimize side effects. Combine with a 500 kcal daily caloric deficit and 150 minutes of exercise per week for best results. Expect significant weight loss (up to 14.7% at 15 mg) within 13 weeks, with side effects like nausea typically subsiding after the titration phase.

A structured primary care intervention combining a phased caloric-restricted diet (initially low-carbohydrate) and progressive aerobic activity, delivered via frequent GP visits, produces statistically significant weight loss (≥5% and ≥10%) compared to usual care in patients with obesity.

If you have obesity, ask your doctor for a structured plan rather than general advice. Look for programs that include frequent check-ins, a written diet guide, and a specific exercise goal. The study showed that a strict 4-week start followed by a balanced diet and daily walking/cycling, managed by your doctor, leads to better weight loss than standard care.

Sedentary lifestyle and insufficient physical activity are significant behavioral factors contributing to obesity by reducing energy expenditure.

Increase daily movement by taking short walks, standing more, or doing light exercises during breaks. Aim for at least 30 minutes of physical activity per day to help control weight.

Dietary factors, including high consumption of refined grains, sugar, fats, and liquid calories, contribute to obesity by increasing caloric intake.

Reduce consumption of sugary beverages, processed foods, and refined grains. Focus on whole foods, fruits, vegetables, and whole grains to manage caloric intake and improve health.

Newer obesity management medications (OMMs), specifically semaglutide (2.4 mg) and tirzepatide (10-15 mg), demonstrate high efficacy comparable to metabolic bariatric surgery (MBS) in the short term (26-52 weeks), with tirzepatide achieving >15% TBWL.

For those seeking non-surgical weight loss, newer medications like semaglutide (2.4 mg) and tirzepatide (10-15 mg) are the most effective options available, with tirzepatide showing short-term weight loss (15.2%) comparable to surgical procedures. These require weekly administration and are generally more effective than older medications like orlistat. They are best used in conjunction with lifestyle interventions.

Combining exercise with pharmacotherapy (specifically GLP-1 agonists or orlistat) significantly enhances weight loss, BMI reduction, and body fat percentage compared to exercise alone in overweight/obese adults.

If you are overweight or obese, adding a prescribed weight-loss medication (like GLP-1 agonists or orlistat) to your regular exercise routine will likely result in greater weight and fat loss than exercising alone. While exercise is foundational, medication can help overcome compensatory mechanisms like increased appetite, leading to more significant improvements in body composition.

A modified-release combination of orlistat (120 mg) and acarbose (40 mg) produces significantly greater weight loss (mean -7.73%) compared to modified-release orlistat alone (-5.78%) or conventional orlistat (-5.13%) over 26 weeks.

Take the specific combination pill (EMP16) containing 120mg modified-release orlistat and 40mg modified-release acarbose daily with meals for 6 months. Follow a diet limiting fat to 30% of calories and focusing on low-glycemic foods. Expect roughly 7.7% body weight loss, which is significantly better than taking orlistat alone.

Low-calorie diets (1,000–1,500 kcal/day) are a foundational, guideline-recommended intervention for obesity management, though weight loss plateaus after 6 months.

Start with a daily intake of 1,000 to 1,500 calories, or a 500-750 calorie deficit, as recommended by major guidelines. Expect the most significant weight loss in the first 6 months, but plan for a maintenance phase afterward. Work with a nutritionist to ensure the diet fits your preferences to improve adherence.

Tirzepatide demonstrates greater comparative weight loss and metabolic benefits than semaglutide in real-world observational studies, particularly in patients without pre-existing diabetes.

If you are using Semaglutide and not achieving your weight loss goals, switching to Tirzepatide may result in greater weight loss and better metabolic outcomes, especially if you do not have Type 2 Diabetes. Real-world data suggests Tirzepatide is more potent than Semaglutide in routine practice.

Plant-based protein sources can stimulate muscle protein synthesis (MPS) and support muscle mass gains comparable to animal proteins when consumed in sufficient quantities, combined to optimize amino acid profiles, and processed to enhance bioavailability.

To build muscle on a plant-based diet, focus on variety and volume. Combine different plant proteins (like beans and rice) in meals to ensure you get all essential amino acids. You may need to eat slightly more total protein (aim for 1.4-2.0 g/kg/day if active) or larger portions of specific proteins (like pea or soy) to hit the leucine threshold needed to trigger muscle growth, similar to how you would with animal proteins.

Processing plant proteins (e.g., isolation, heating, fermentation) significantly improves their digestibility and bioavailability, making them more effective for MPS than raw plant foods.

If you struggle to eat enough plant protein from whole foods alone, consider using plant protein isolates or concentrates (like pea or soy isolate). These are processed to remove anti-nutrients that block digestion, making the protein much more available for your muscles than raw beans or grains.

Low energy availability (LEA) of 25 kcal/kg fat-free mass per day significantly reduces daily integrated myofibrillar and sarcoplasmic muscle protein synthesis in trained females, even when protein intake is maintained at 2.2 g/kg lean mass per day.

If you are a trained female athlete trying to build or maintain muscle while in a caloric deficit, simply eating high protein is not enough. You must ensure your energy availability is sufficient (above ~30 kcal/kg fat-free mass). Severe energy restriction will blunt muscle protein synthesis and lean mass gains, even with optimal protein intake. Focus on balancing energy intake with exercise expenditure.

Cognitive-behavioral treatment for obesity, delivered in weekly group sessions for 4-6 months, typically produces an 8-10% reduction in initial body weight, which is associated with clinically meaningful improvements in chronic conditions.

Commit to a structured program that meets weekly for 4-6 months. Focus on tracking your food and activity, setting specific weekly goals, and learning to handle setbacks as learning opportunities rather than failures. To keep the weight off, stay in touch with the program or a support group after the initial 6 months.

GLP-1/GIP co-agonists (e.g., tirzepatide) induce greater weight loss and have a more favorable gastrointestinal tolerability profile compared to GLP-1 monotherapy (e.g., semaglutide or liraglutide).

If you are considering GLP-1 therapy for obesity, discuss the potential benefits of dual agonists like tirzepatide with your provider. They may offer greater weight loss and potentially fewer gastrointestinal side effects compared to GLP-1 monotherapy, although individual responses vary.